Pioneering Cutting-edge Research into Clinical Science Designed to Protect and Preserve the Human Gut Microbiome


Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company’s lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR) and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

Our Lead Candidates

SYN-004 (ribaxamase)

SYN-004 (ribaxamase) is an oral enzyme tablet engineered to survive the stomach thereby allowing IV beta-lactam antibiotics to treat infection while SYN-004 protects and preserves the naturally occurring gut microbiome from dysbiosis which can lead to the onset of antibiotic-mediated primary C. difficile infection, pathogenic colonization, the emergence antimicrobial resistance, and acute graft versus host disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients.

View SYN-004 (ribaxamase)


SYN-020 is a recombinant version of bovine Intestinal Alkaline Phosphatase (IAP) produced under cGMP conditions and formulated for oral delivery. The diverse mechanisms of IAP action indicate that SYN-020 may have utility in a broad range of therapeutic indications, including radiation enteropathy associated with the treatment of pelvic cancers, and indications related to the use of IAP to maintain GI and microbiome health, diminish systemic inflammation, and treat age-related diseases.

View SYN-020

Protecting the Gut Microbiome

Your body has 10 times as many microbe cells as human cells.
We’re leveraging the microbiome to radically change today’s medicine.

Watch Video

tech video

How SYN-004 (ribaxamase) Works

SYN-004 is an oral prophylactic therapy designed to degrade residual and still viable IV beta-lactam antibiotics which pass through the GI tract following systemic circulation.


Our experienced management team has an extensive clinical and commercial track record.